The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The potential for self-administration to transform multiple myeloma care
In this video, Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, briefly discusses the benefits of self-administration in multiple myeloma (MM), highlighting its potential to improve clinical care and patient quality of life by allowing them to fit treatment around their daily responsibilities and activities. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think self-administration of any treatment is really beneficial for patients because it means that they can fit their treatment around the rest of their life, whether that be work, caring responsibilities or other things that they want to enjoy. Lots of the medications we use in myeloma are tablet-based and clearly they are easy to take at home, but several of the medications we use have previously had to be given within a hospital setting and so it’s really important for patients that we try and work out ways to deliver these either closer to a patient’s home, within a patient’s home or even by the patient themselves to enable the maximum flexibility for them to receive treatment safely but around the rest of their life...
I think self-administration of any treatment is really beneficial for patients because it means that they can fit their treatment around the rest of their life, whether that be work, caring responsibilities or other things that they want to enjoy. Lots of the medications we use in myeloma are tablet-based and clearly they are easy to take at home, but several of the medications we use have previously had to be given within a hospital setting and so it’s really important for patients that we try and work out ways to deliver these either closer to a patient’s home, within a patient’s home or even by the patient themselves to enable the maximum flexibility for them to receive treatment safely but around the rest of their life.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
